258 related articles for article (PubMed ID: 20558734)
21. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
[TBL] [Abstract][Full Text] [Related]
22. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.
Seeman E; Delmas PD; Hanley DA; Sellmeyer D; Cheung AM; Shane E; Kearns A; Thomas T; Boyd SK; Boutroy S; Bogado C; Majumdar S; Fan M; Libanati C; Zanchetta J
J Bone Miner Res; 2010 Aug; 25(8):1886-94. PubMed ID: 20222106
[TBL] [Abstract][Full Text] [Related]
23. Twelve Months of Denosumab and/or Alendronate Is Associated With Improved Bone Fatigue Life, Microarchitecture, and Density in Ovariectomized Cynomolgus Monkeys.
Haider IT; Loundagin LL; Sawatsky A; Kostenuik PJ; Boyd SK; Edwards WB
J Bone Miner Res; 2023 Mar; 38(3):403-413. PubMed ID: 36533719
[TBL] [Abstract][Full Text] [Related]
24. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH.
Saini V; Marengi DA; Barry KJ; Fulzele KS; Heiden E; Liu X; Dedic C; Maeda A; Lotinun S; Baron R; Pajevic PD
J Biol Chem; 2013 Jul; 288(28):20122-34. PubMed ID: 23729679
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation.
Idris AI; Greig IR; Bassonga-Landao E; Ralston SH; van 't Hof RJ
Endocrinology; 2009 Jan; 150(1):5-13. PubMed ID: 18772231
[TBL] [Abstract][Full Text] [Related]
26. A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment.
Altman AR; Tseng WJ; de Bakker CM; Huh BK; Chandra A; Qin L; Liu XS
Bone; 2014 Apr; 61():149-57. PubMed ID: 24468717
[TBL] [Abstract][Full Text] [Related]
27. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
[TBL] [Abstract][Full Text] [Related]
28. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
Miller PD; Bolognese MA; Lewiecki EM; McClung MR; Ding B; Austin M; Liu Y; San Martin J
Bone; 2008 Aug; 43(2):222-229. PubMed ID: 18539106
[TBL] [Abstract][Full Text] [Related]
29. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
30. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts.
Li X; Qin L; Bergenstock M; Bevelock LM; Novack DV; Partridge NC
J Biol Chem; 2007 Nov; 282(45):33098-106. PubMed ID: 17690108
[TBL] [Abstract][Full Text] [Related]
31. Differential transcriptional effects of PTH and estrogen during anabolic bone formation.
von Stechow D; Zurakowski D; Pettit AR; Müller R; Gronowicz G; Chorev M; Otu H; Libermann T; Alexander JM
J Cell Biochem; 2004 Oct; 93(3):476-90. PubMed ID: 15372627
[TBL] [Abstract][Full Text] [Related]
32. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
Wang L; Quarles LD; Spurney RF
J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
[TBL] [Abstract][Full Text] [Related]
33. Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.
Chiu YG; Ritchlin CT
Expert Opin Biol Ther; 2017 Jan; 17(1):119-128. PubMed ID: 27871200
[TBL] [Abstract][Full Text] [Related]
34. Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2.
Ferrari SL; Pierroz DD; Glatt V; Goddard DS; Bianchi EN; Lin FT; Manen D; Bouxsein ML
Endocrinology; 2005 Apr; 146(4):1854-62. PubMed ID: 15705780
[TBL] [Abstract][Full Text] [Related]
35. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
[TBL] [Abstract][Full Text] [Related]
36. Differing Effects of Parathyroid Hormone, Alendronate, and Odanacatib on Bone Formation and on the Mineralization Process in Intracortical and Endocortical Bone of Ovariectomized Rabbits.
Vrahnas C; Buenzli PR; Pearson TA; Pennypacker BL; Tobin MJ; Bambery KR; Duong LT; Sims NA
Calcif Tissue Int; 2018 Dec; 103(6):625-637. PubMed ID: 30019315
[TBL] [Abstract][Full Text] [Related]
37. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
38. The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.
Yang Y; Blair HC; Shapiro IM; Wang B
J Biol Chem; 2015 Jul; 290(27):16918-28. PubMed ID: 25979341
[TBL] [Abstract][Full Text] [Related]
39. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
Beck TJ; Lewiecki EM; Miller PD; Felsenberg D; Liu Y; Ding B; Libanati C
J Clin Densitom; 2008; 11(3):351-9. PubMed ID: 18495508
[TBL] [Abstract][Full Text] [Related]
40. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin.
Ihara H; Denhardt DT; Furuya K; Yamashita T; Muguruma Y; Tsuji K; Hruska KA; Higashio K; Enomoto S; Nifuji A; Rittling SR; Noda M
J Biol Chem; 2001 Apr; 276(16):13065-71. PubMed ID: 11278791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
